Evaluation of Colorectal Cancer Incidence Trends in the United States (2000-2014)
- PMID: 29385768
- PMCID: PMC5852438
- DOI: 10.3390/jcm7020022
Evaluation of Colorectal Cancer Incidence Trends in the United States (2000-2014)
Abstract
Colorectal cancer (CRC) incidence rates have declined in recent years for people of all races/ethnicities; however, the extent to which the decrease varies annually by demographic and disease-related characteristics is largely unknown. This study examines trends and annual percent change (APC) in the incidence among persons diagnosed with CRC in the United States of America from 2000-2014. The data obtained from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program were analyzed, and all persons (N = 577,708) with malignant CRC recorded in the SEER 18 database from 2000 to 2014 were characterized according to sex, race, age at diagnosis, disease site and stage. Incidence rates and APC were calculated for the entire study period. Overall, the incidence rate of CRC decreased from 54.5 in 2000 to 38.6 per 100,000 in 2014, with APC = -2.66 (p < 0.0001). Decline in rates was most profound between 2008 and 2011 from 46.0 to 40.7 per 100,000 (APC = -4.04; p < 0.0001). Rates were higher for males (vs. females; rate ratio (RR) = 1.33) and for blacks (vs. whites; RR = 1.23). Proximal colon cancers at the localized stage were the predominant cancers. An increase in rate was observed among people younger than 50 years (6.6 per 100,000, APC= 1.5). The annual rate of CRC has decreased over time. However, the development and implementation of interventions that further reduce the disparities among demographic and disease-related subgroups are warranted.
Keywords: Colorectal cancer; SEER; annual percent change; incidence; rates.
Conflict of interest statement
The authors declare no conflict of interest. The funding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.
Figures




Similar articles
-
Colorectal cancer incidence in the United States, 1999-2004 : an updated analysis of data from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results Program.Cancer. 2009 May 1;115(9):1967-76. doi: 10.1002/cncr.24216. Cancer. 2009. PMID: 19235249
-
Decrease in Incidence of Colorectal Cancer Among Individuals 50 Years or Older After Recommendations for Population-based Screening.Clin Gastroenterol Hepatol. 2017 Jun;15(6):903-909.e6. doi: 10.1016/j.cgh.2016.08.037. Epub 2016 Sep 5. Clin Gastroenterol Hepatol. 2017. PMID: 27609707 Free PMC article.
-
Secular changes in colorectal cancer incidence by subsite, stage at diagnosis, and race/ethnicity, 1992-2001.Cancer. 2006 Sep 1;107(5 Suppl):1142-52. doi: 10.1002/cncr.22011. Cancer. 2006. PMID: 16835912
-
Plasma Cell Myeloma - 20-Year Comparative Survival and Mortality of Three Plasma Cell Myeloma ICD-O-3 Oncologic Phenotypes by Age, Sex, Race, Stage, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 111,041 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).J Insur Med. 2018;47(4):203-211. doi: 10.17849/insm-47-04-1-9.1. Epub 2019 Jan 22. J Insur Med. 2018. PMID: 30668210
-
20-Year Comparative Survival and Mortality of Cancer of the Stomach by Age, Sex, Race, Stage, Grade, Cohort Entry Time-Period, Disease Duration & Selected ICD-O-3 Oncologic Phenotypes: A Systematic Review of 157,258 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).J Insur Med. 2019;48(1):5-23. doi: 10.17849/insm-48-1-1-19.1. Epub 2019 Oct 14. J Insur Med. 2019. PMID: 31609640
Cited by
-
Cannabinoid Effects on Experimental Colorectal Cancer Models Reduce Aberrant Crypt Foci (ACF) and Tumor Volume: A Systematic Review.Evid Based Complement Alternat Med. 2020 Jul 20;2020:2371527. doi: 10.1155/2020/2371527. eCollection 2020. Evid Based Complement Alternat Med. 2020. PMID: 32765628 Free PMC article. Review.
-
Evolution of colorectal cancer screening research in the past 25 years: text-mining analysis of publication trends and topics.Therap Adv Gastroenterol. 2020 Jul 20;13:1756284820941153. doi: 10.1177/1756284820941153. eCollection 2020. Therap Adv Gastroenterol. 2020. PMID: 32733602 Free PMC article.
-
PI3K/AKT signaling pathway as a critical regulator of epithelial-mesenchymal transition in colorectal tumor cells.Cell Commun Signal. 2023 Aug 14;21(1):201. doi: 10.1186/s12964-023-01225-x. Cell Commun Signal. 2023. PMID: 37580737 Free PMC article. Review.
-
NEBL and AKT1 maybe new targets to eliminate the colorectal cancer cells resistance to oncolytic effect of vesicular stomatitis virus M-protein.Mol Ther Oncolytics. 2021 Nov 24;23:593-601. doi: 10.1016/j.omto.2021.11.013. eCollection 2021 Dec 17. Mol Ther Oncolytics. 2021. PMID: 34977336 Free PMC article.
-
Evidenced-Based Screening Strategies for a Positive Family History.Gastrointest Endosc Clin N Am. 2020 Jul;30(3):597-609. doi: 10.1016/j.giec.2020.02.015. Epub 2020 Apr 14. Gastrointest Endosc Clin N Am. 2020. PMID: 32439091 Free PMC article. Review.
References
-
- United States Cancer Statistics Working Group 1999–2013 Incidence and Mortality Web-Based Report. [(accessed on 8 May 2017)]; Available online: http://www.cdc.gov/uscs.
-
- American Cancer Society . Colorectal Cancer Facts & Figures 2017-2019. American Cancer Society; Atlanta, GA, USA: 2017. [(accessed on 8 May 2017)]. Available online: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-....
-
- Division of Cancer Prevention and Control, Centers for Disease Control and Prevention 2016. [(accessed on 8 May 2017)]; Available online: https://www.cdc.gov/cancer/colorectal/basic_info/risk_factors.htm.
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources